Design, synthesis, and structure-activity relationship of a novel series of 2-aryl 5-(4-oxo-3-phenethyl-2-thioxothiazolidinylidenemethyl)furans as HIV-1 entry inhibitors

Journal of Medicinal Chemistry

Volumn 52, Issue 23, 2009, Pages 7631-7639

  Katritzky, Alan R ^a   Tala, Srinivasa R ^a   Lu, Hong ^b   Vakulenko, Anatoliy V ^a   Chen, Qi Yin ^a   Sivapackiam, Jothilingam ^a   Pandya, Keyur ^a   Jiang, Shibo ^b   Debnath, Asim K ^b  

^a University of Florida ^*  (United States)

^b NEW YORK BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARYL 5 ( 4 OXO 3 PHENETHYL 2 THIOXOTHIAZOLIDINYLIDENE METHYL)FURAN; 2 BROMO 5 ( 5 [ 4 OXO 3 PHENETHYL 2 THIOXOTHIAZOLIDIN 5 YLIDENEMETHYL]FURAN 2 YL)BENZOIC ACID; 2 BROMO 5 ( 5 [ 4 OXO 3 PHENETHYL 2 THIOXOTHIAZOLIDIN 5 YLIDENEMETHYL]FURAN 2 YL)NICOTINIC ACID HEMI 2,2,6,6 TETRAMETHYLPIPERIDINE DIHYDRATE; 2 CHLORO 3 ( 5 [ 4 OXO 3 PHENETHYL 2 THIOXOTHIAZOLIDIN 5 YLIDENEMETHYL]FURAN 2 YL)BENZOIC ACID; 2 CHLORO 5 ( 5 [ 4 OXO 3 PHENETHYL 2 THIOXOTHIAZOLIDIN 5 YLIDENEMETHYL]FURAN 2 YL)BENZOIC ACID; 2 CHLORO 5 ( 5 [ 4 OXO 3 PHENETHYL 2 THIOXOTHIAZOLIDIN 5 YLIDENEMETHYL]FURAN 2 YL)NICOTINIC ACID; 2 ETHYL 5 ( 5 [ 4 OXO 3 PHENETHYL 2 THIOXOTHIAZOLIDIN 5 YLIDENEMETHYL]FURAN 2 YL)BENZOIC ACID; 2 FLUORO 3 ( 5 [ 4 OXO 3 PHENETHYL 2 THIOXOTHIAZOLIDIN 5 YLIDENEMETHYL]FURAN 2 YL )BENZOIC ACID; 2 FLUORO 5 ( 5 [ 4 OXO 3 PHENETHYL 2 THIOXOTHIAZOLIDIN 5 YLIDENEMETHYL]FURAN 2 YL)BENZOIC ACID; 2 HYDROXY 5 ( 5 [ 4 OXO 3 PHENETHYL 2 THIOXOTHIAZOLIDIN 5 YLIDENEMETHYL]FURAN 2 YL)BENZOIC ACID; 2 METHOXY 5 ( 5 [ 4 OXO 3 PHENETHYL 2 THIOXOTHIAZOLIDIN 5 YLIDENEMETHYL]FURAN 2 YL)BENZOIC ACID; 2 METHYL 3 ( 5 [ 4 OXO 3 PHENETHYL 2 THIOXOTHIAZOLIDIN 5 YLIDENEMETHYL]FURAN 2 YL)BENZOIC ACID; 2 METHYL 5 ( 5 [ 4 OXO 3 PHENETHYL 2 THIOXOTHIAZOLIDIN 5 YLIDENEMETHYL]FURAN 2 YL)BENZOIC ACID; 3 ( 5 [ 4 OXO 3 PHENETHYL 2 THIOXOTHIAZOLIDIN 5 YLIDENEMETHYL]FURAN 2 YL)BENZOIC ACID; 4 METHYL 5 ( 5 [ 4 OXO 3 PHENETHYL 2 THIOXOTHIAZOLIDIN 5 YLIDENEMETHYL]FURAN 2 YL)NICOTINIC ACID; 5 ( 5 [ 4 OXO 3 PHENETHYL 2 THIOXOTHIAZOLIDIN 5 YLIDENEMETHYL]FURAN 2 YL)NICOTINIC ACID; ANTIRETROVIRUS AGENT; BENZOIC ACID DERIVATIVE; FURAN DERIVATIVE; N ( 3 CARBOXY 4 CHLORO)PHENYLPYRROLE; N ( 4 CARBOXY 3 HYDROXY)PHENYL 2,5 DIMETHYLPYRROLE; NICOTINIC ACID DERIVATIVE; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS GLYCOPROTEIN 41;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CROSS COUPLING REACTION; CYTOTOXICITY; DRUG DESIGN; DRUG INHIBITION; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; KNOEVENAGEL CONDENSATION; MOLECULE; PARTICLE SIZE; PROTEIN TARGETING; STRUCTURE ACTIVITY RELATION; SUZUKI REACTION; VIRUS REPLICATION;

ANTI-HIV AGENTS; CELL LINE; DRUG DESIGN; FURANS; HIV ENVELOPE PROTEIN GP41; HIV-1; MODELS, MOLECULAR; MOLECULAR WEIGHT; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS INTERNALIZATION;

EID: 72249122328     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900450n     Document Type: Article

References (34)

1. Fauci, A. S. 25 years of HIV. Nature 2008, 453, 289-290.
2. Walker, B. D.; Burton, D. R. Towards an AIDS vaccine. Science 2008, 320, 760-764.
3. De Clercq, E. Antiviral drugs in current clinical use. J. Clin. Virol. 2004, 30, 115-133.
4. Johnson, V. A.; Brun-Vezinet, F.; Clotet, B.; Conway, B.; D'Aquila, R. T.; Demeter, L. M.; Kuritzkes, D. R.; Pillay, D.; Schapiro, J. M.; Telenti, A.; Richman, D. D. Drug resistancemutations in HIV-1. Top. HIV Med. 2003, 11, 215-221.
5. Richman, D. D.; Morton, S. C.; Wrin, T.; Hellmann, N.; Berry, S.; Shapiro, M. F.; Bozzette, S. A. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004, 18, 1393-1401. (Pubitemid 38925131)
6. Carr, A.; Cooper, D. A. Adverse effects of antiretroviral therapy. Lancet 2000, 356, 1423-1430.
7. Berger, E. A. HIV entry and tropism: the chemokine receptor connection. AIDS 1997, 11, 3-16.
8. Chan, D. C.; Kim, P. S. HIV entry and its inhibition. Cell 1998, 93, 681-684.
9. Liu, S.; Wu, S.; Jiang, S. HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds. Curr. Pharm. Des. 2007, 13, 143-162.
10. Jiang, S.; Lin, K.; Strick, N.; Neurath, A. R. HIV-1 inhibition by a peptide. Nature 1993, 365, 113.
11. Wild, C. T.; Shugars, D. C.; Greenwell, T. K.; McDanal, C. B.; Matthews, T. J. Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 9770-9774.
12. Lu, M.; Blacklow, S. C.; Kim, P. S. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. 1995, 2, 1075-1082.
13. Chan, D. C.; Fass, D.; Berger, J. M.; Kim, P. S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997, 89, 263-273.
14. Weissenhorn, W.; Dessen, A.; Harrison, S. C.; Skehel, J. J.; Wiley, D. C. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997, 387, 426-430. (Pubitemid 27227210)
15. Kilby, J. M.; Eron, J. J. Novel therapies based on mechanisms of HIV-1 cell entry. N. Engl. J. Med. 2003, 348, 2228-2238.
16. Lalezari, J. P.; Henry, K.; O'Hearn, M.; Montaner, J. S. G.; Piliero, P. J.; Trottier, B.; Walmsley, S.; Cohen, C.; Kuritzkes, D. R.; Eron, J. J., Jr; Chung, J.; DeMasi, R.; Donatacci, L.; Drobnes, C.; Delehanty, J.; Salgo, M. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 2003, 348, 2175-2185.
17. Liu, S.; Boyer-Chatenet, L.; Lu, H.; Jiang, S. Rapid and automated fluorescence-linked immunosorbent assay for high throughput screening of HIV-1 fusion inhibitors targeting gp41. J. Biomol. Screening 2003, 8, 685-693. (Pubitemid 40503577)
18. Jiang, S.; Lu, H.; Liu, S.; Zhao, Q.; He, Y.; Debnath, A. K. N-Substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob. Agents Chemother. 2004, 48, 4349-4359.
19. Debnath, A. K.; Radigan, L.; Jiang, S. Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodecifiency virus type 1. J. Med. Chem. 1999, 42, 3203-3209.
20. Robert, N.; Bonneau, A-.; Hoarau, C.; Marsais, F. Unusual sterically controlled regioselective lithiation of 3-bromo-5-(4,4′-dimethyl) oxazolinylpyridine. Straightforward access to highly substituted nicotinic acid derivatives. Org. Lett. 2006, 8, 6071-6074.
21. Buck, J. S.; Leonard, C. S. Rhodanines. I. Derivatives of β-phenylethylamines. J. Am. Chem. Soc. 1931, 53, 2688-2692.
22. Miyaura, N.; Suzuki, A. Palladium-catalyzed cross-coupling reactions of organoboron compounds. Chem. Rev. 1995, 95, 2457-2483.
23. Kotha, S.; Lahiri, K.; Kashinath, D. Recent applications of the Suzuki-Miyaura cross-coupling reaction in organic synthesis. Tetrahedron 2002, 58, 9633-9695. (Pubitemid 35356429)
24. 2+ release from sarcoplasmic reticulum of mouse skeletal muscle. Bioorg. Med. Chem. 2003, 11, 663-673.
25. Bumagin, N. A.; Bykov, V. V. Ligandless palladium catalyzed reactions of arylboronic acids and sodium tetraphenylborate with aryl halides in aqueous media. Tetrahedron 1997, 53, 14437-14450.
26. Lee, C. L.; Sim, M. M. Solid-phase combinatorial synthesis of 5-arylalkylidene rhodanine. Tetrahedron Lett. 2000, 41, 5729-5732. (Pubitemid 30483352)
27. Lohray, B. B.; Bhushan, V.; Rao, P. B.; Madhavan, G. R.; Murali, N.; Rao, K. N.; Reddy, K. A.; Rajesh, B. M.; Reddy, P. G.; Chakrabarti, R.; Rajagopalan, R. Novel indole containing thiazolidinedione derivatives as potent euglycemic and hypolipidaemic agents. Bioorg. Med. Chem. Lett. 1997, 7, 785-788.
28. Singh, S. P.; Parmar, S. S.; Raman, K.; Stenberg, V. I. Chemistry and biological activity of thiazolidinones. Chem. Rev. 1981, 81, 175-203.
29. Parry, P. R.; Bryce, M. R.; Tarbit, B. 5-Formyl-2-furylboronic acid as a versatile bifunctional reagent for the synthesis of π-extended heteroarylfuran systems. Org. Biomol. Chem. 2003, 1, 1447-1449.
30. Korolev, D. N.; Bumagin, N. A. Pd-EDTA as an efficient catalyst for Suzuki-Miyaura reactions in water. Tetrahedron Lett. 2005, 46, 5751-5754. (Pubitemid 41019182)
31. Zhao, Q.; Ma, L.; Jiang, S.; Lu, H.; Liu, S.; He, Y.; Strick, N.; Neamati, N.; Debnath, A. K. Identification of N-phenyl-N′-(2,2,6,6- tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology 2005, 339, 213-225.
32. Chou, T. C.; Hayball, M. P. CalcuSyn: Windows Software for Dose Effect Analysis; BIOSOFT: Ferguson, MO, 1991.
33. Gohier, F.; Mortier, J. Ortho-metalation of unprotected 3-bromo and 3-chlorobenzoic acids with hindered lithium dialkylamides. J. Org. Chem. 2003, 68, 2030-2033.
34. Setliff, F. L.; Greene, J. S. Some 2,5- and 5,6-dihalonicotinic acids and their precursors. J. Chem. Eng. Data 1978, 23, 96-97.